Rheumnow Podcast
1,029 episodes — Page 7 of 21
Ep 1208The Crossroads of Autoinflammation and Autoimmunity
Dr. Andrea Fava shares his perspectives on autoinflammation and autoimmunity at Eular 2024 in Vienna, Austria.
Ep 1207Cognitive Function in Older Adults with Lupus
Dr. Mrinalini Dey discusses abstract POS0730 presented at Eular 2024 in Vienna, Austria.
Ep 1206Inspirations About RA-ILD
Dr. Jonathan Kay discusses abstracts POS0070, POS0043 and POS0022 presented at the Eular 2024 meeting in Vienna, Austria.
Ep 1205Abatacept Misses on Shingrix Response
Dr. David Liew discusses abstract POS0620 at Eular 2024 in Vienna, Austria.
Ep 1204Artificial Intelligence Detection of CPPD on Hand Radiographs
Dr. Antoni Chan interviews Dr. Thomas Hugle about abstract OP0112 presented at Eular 2024 in Vienna, Austria.
Ep 1203Cognitive Function in Older Adults with Lupus
Dr. Mrinalini Dey discusses abstract POS0730 presented at Eular 2024 in Vienna, Austria.
Ep 1202Has JAK POT Hit the Spot About Infection Risk?
Dr. Yuz Yusof discusses abstract OP0092 presented at Eular 2024 in Vienna, Austria.
Ep 1201Select your GCA Therapy
Dr. David Liew discusses LBA0001 presented at Eular 2024 in Vienna, Austria.
Ep 1200DMARDs and Herpes Zoster Vaccination: To Stop or Not To Stop
Dr. Jonathan Kay discusses abstracts POS0620 and OP0020 presented at Eular 2024 in Vienna, Austria.
Ep 1199EULAR 2024 Daily Recap Days 1 & 2
Dr. Jack Cush moderates EULAR 2024 RECAP for days 1 & 2 with Drs. Mrinalini Day and Yuz Yusof in Vienna, Austria. OP0156
Ep 1198EULAR 2024 Daily Recap: Days 1 & 2
Dr. Jack Cush moderates EULAR 2024 RECAP for days 1 & 2 with Drs. Mrinalini Day and Yuz Yusof in Vienna, Austria.
Ep 1197Has JAK POT Hit the Spot About Infection Risk?
Dr. Yuz Yusof discusses abstract OP0092 presented at Eular 2024 in Vienna, Austria.
Ep 1196Difficult-to-treat Rheumatoid Arthritis Validation of the EULAR Definition
Dr. Mrinalini Dey discusses abstract OP0156 presented at Eular 2024 in Vienna, Austria.
Ep 1195DMARDs and Herpes Zoster Vaccination To Stop or Not To Stop
Dr. Jonathan Kay discusses abstracts POS0620 and OP0020 presented at Eular 2024 in Vienna, Austria.
Ep 1194Does Withdrawing Steroids Increase Flares in SLE?
Dr. Janet Pope reports on abstract OP0180 presented at Eular 2024 in Vienna, Austria.
Ep 1193We've Got to Talk about CAR T cells
Dr. Yuz Yusof discusses abstract OP0017 presented at the Eular 2024 meeting in Vienna, Austria.
Ep 1192EULAR 2024 Daily Podcasts Day1&2
Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis? Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria: OP0195 Sonelokimab IL 17 A/F nanobody inhibitor LB0005 Izokibep IL17A nanobody inhibitor POS0803 Vunakizumab, another IL17A inhibitor OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib Transition from Psoriasis to PsA: Can we Prevent It? Dr. Aurelie Najm discusses abstract OP0010 presented at Eular 2024 in Vienna, Austria. JAK Inhibitors for New Indications Dr. Janet Pope discusses new indications for JAK inhibitors, reporting from Eular 2024 in Vienna, Austria. PsA Treatment: is Earlier Better? Dr. Aurelie Najm discusses abstract OP0184, presented at Eular 2024 in Vienna, Austria. Do MRI changes at the Spine and SI Joints in Treatment of AxSpA Matter? Dr. Eric Ruderman discusses abstracts OP0046 and POS0058 presented at Eular 2024 in Vienna, Austria. OP0046 Effect on SI joint structural lesions with ixekizumab POS0058 Effect on SI joint structural lesions with bimekizumab Does Telemonitoring in SpA Work? Dr. Antoni Chan reports on abstract OP0120 from Eular 2024 in Vienna, Austria. Treat to Target Outcomes in Early AxSpA Dr. Antoni Chan discusses abstract OP0132 presented at Eular 2024 in Vienna, Austria. Potential of Radiomics to Predict TNF Therapy Outcomes in axSpA Dr. Bella Mehta interviews Dr. Vincenzo Venerito about abstract POS0236 at Eular 2024 in Vienna, Austria. Pain in RA: Different Drugs for Different Mechanisms Dr. Aurelie Najm reports from Eular 2024 in Vienna, Austria, about abstracts OP0072 and OP0086. Top 3 Messages About JAK Inhibitor Safety Dr. Janet Pope discusses a debate she participated in at Eular 2024 in Vienna, Austria, and her top three messages regarding JAKi safety. Giant Cell Arteritis and Polymyalgia Rheumatica Update Dr. Janet Pope discusses abstracts LBA0001, OP0233, OP0261 and POS0280 at Eular 2024 in Vienna, Austria. Does B Cell Depletion Matter? Drs. Yuz Yusof and Ed Vital discuss abstract OP0077 at Eular 2024 in Vienna, Austria. 3 Big Lupus Themes from EULAR 2024 Dr. Janet Pope discusses three hot topics in lupus at Eular 2024 in Vienna, Austria. Voclosporin and Steroids in Lupus Nephritis Dr. Jack Cush reports on abstract OP0059 presented at Eular 2024 in Vienna, Austria. The Role of Psychosocial Determinants in the Management of Rheumatoid Arthritis Dr. Mrinalini Dey reports from Eular 2024 in Vienna, Austria about an abstract she will present during the meeting, POS0309. Mechanistic Promise in RA Doesn’t Always Mean Actual Gain Dr. David Liew reports on abstracts OP0007 and OP0069 at Eular 2024 in Vienna, Austria. Pain in RA: Different Drugs for Different Mechanisms Dr. Aurelie Najm reports from Eular 2024 in Vienna, Austria, about abstracts OP0072 and OP0086. Top 3 Messages About JAK Inhibitor Safety Dr. Janet Pope discusses a debate she participated in at Eular 2024 in Vienna, Austria, and her top three messages regarding JAKi safety. A Step Closer to Identifying Phenotypes of RA ILD Dr. Mrinalini Dey discusses abstract OP0202 presented at Eular 2024 in Vienna, Austria. Predicting Palindromic Prognosis Dr. David Liew discusses abstract OP0127 at Eular 2024 in Vienna, Austria.
Ep 1191Predicting Palindromic Prognosis
Dr. David Liew discusses abstract OP0127 at Eular 2024 in Vienna, Austria.
Ep 1190A Step Closer to Identifying Phenotypes of RA ILD
Dr. Mrinalini Dey discusses abstract OP0202 presented at Eular 2024 in Vienna, Austria.
Ep 1189Top 3 Messages About JAK Inhibitor Safety
Dr. Janet Pope discusses a debate she participated in at Eular 2024 in Vienna, Austria, and her top three messages regarding JAKi safety.
Ep 1188Pain in RA: Different Drugs for Different Mechanisms
Dr. Aurelie Najm reports from Eular 2024 in Vienna, Austria, about abstracts OP0072 and OP0086.
Ep 1187Giant Cell Arteritis and Polymyalgia Rheumatica Update
Dr. Janet Pope discusses abstracts LBA0001, OP0233, OP0261 and POS0280 at Eular 2024 in Vienna, Austria.
Ep 1186JAK Inhibitors for New Indications
Dr. Janet Pope discusses new indications for JAK inhibitors, reporting from Eular 2024 in Vienna, Austria.
Ep 1185Top 3 Messages About JAK Inhibitor Safety
Dr. Janet Pope discusses a debate she participated in at Eular 2024 in Vienna, Austria, and her top three messages regarding JAKi safety.
Ep 1184Pain in RA: Different Drugs for Different Mechanisms
Dr. Aurelie Najm reports from Eular 2024 in Vienna, Austria, about abstracts OP0072 and OP0086.
Ep 1183JAK Inhibitors for New Indications
Dr. Janet Pope discusses new indications for JAK inhibitors, reporting from Eular 2024 in Vienna, Austria.
Ep 1182Potential of Radiomics to Predict TNF Therapy Outcomes in axSpA
Dr. Bella Mehta interviews Dr. Vincenzo Venerito about abstract POS0236 at Eular 2024 in Vienna, Austria.
Ep 1181Treat to Target Outcomes in Early AxSpA
Dr. Antoni Chan discusses abstract OP0132 presented at Eular 2024 in Vienna, Austria.
Ep 1180Does Telemonitoring in SpA Work?
Dr. Antoni Chan reports on abstract OP0120 from Eular 2024 in Vienna, Austria.
Ep 1179PsA Treatment: is Earlier Better?
Dr. Aurelie Najm discusses abstract OP0184, presented at Eular 2024 in Vienna, Austria.
Ep 1178JAK Inhibitors for New Indications
Dr. Janet Pope discusses new indications for JAK inhibitors, reporting from Eular 2024 in Vienna, Austria.
Ep 1177Transition from Psoriasis to PsA: Can we Prevent It?
Dr. Aurelie Najm discusses abstract OP0010 presented at Eular 2024 in Vienna, Austria.
Ep 1176EULAR 2024 Daily Recap - Days 1 & 2
Moderated by Dr. Jack Cush and featuring Dr. Yuz Yusof and Dr. Mrinalini Dey
Ep 1175Mechanistic Promise in RA Doesn’t Always Mean Actual Gain
Dr. David Liew reports on abstracts OP0007 and OP0069 at Eular 2024 in Vienna, Austria.
Ep 1174The Role of Psychosocial Determinants in the Management of Rheumatoid Arthritis
Dr. Mrinalini Dey reports from Eular 2024 in Vienna, Austria about an abstract she will present during the meeting, POS0309.
Ep 1173Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?
Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria: OP0195 Sonelokimab IL 17 A/F nanobody inhibitor LB0005 Izokibep IL17A nanobody inhibitor POS0803 Vunakizumab, another IL17A inhibitor OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib
Ep 1172Voclosporin and Steroids in Lupus Nephritis
Dr. Jack Cush reports on abstract OP0059 presented at Eular 2024 in Vienna, Austria.
Ep 11713 Big Lupus Themes from EULAR 2024
Dr. Janet Pope discusses three hot topics in lupus at Eular 2024 in Vienna, Austria.
Ep 1170Does B Cell Depletion Matter?
Drs. Yuz Yusof and Ed Vital discuss abstract OP0077 at Eular 2024 in Vienna, Austria.
Ep 1169Do MRI changes at the Spine and SI Joints in Treatment of AxSpA Matter?
Dr. Eric Ruderman discusses abstracts OP0046 and POS0058 presented at Eular 2024 in Vienna, Austria. OP0046 Effect on SI joint structural lesions with ixekizumab POS0058 Effect on SI joint structural lesions with bimekizumab
Ep 1168Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?
Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria: OP0195 Sonelokimab IL 17 A/F nanobody inhibitor LB0005 Izokibep IL17A nanobody inhibitor POS0803 Vunakizumab, another IL17A inhibitor OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib
Ep 1167Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?
Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria: OP0195 Sonelokimab IL 17 A/F nanobody inhibitor LB0005 Izokibep IL17A nanobody inhibitor POS0803 Vunakizumab, another IL17A inhibitor OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib
Ep 1166Is Cannabis Safe? (6.7.2024)
Dr. Jack Cush reviews FDA approval, news and journal articles -- Its the week before EULAR 2024 in Vienna!!
Ep 1165ACR’s Run at Goliath (PCPs) (5.31.2024)
Dr. Jack Cush reviews the journal reports and articles from this past week on RheumNow.com. The ACR (and Cush) address their new website designed to educate PCPs and APP's - what do you think?
Ep 1164The Window of Opportunity (5.24.2024)
Dr. Jack Cush reviews the journal reports and news from the past week on RheumNow.com. This week blockbuster drugs, opioids in rheumatology and nontreatment of inflammatory arthritis?
Ep 1163Don't You Know Who I am (5.17.2024)
Dr. Jack Cush reviews the news and journal reports from the past 2 weeks. This weeks question - Can we prevent gout, ILD or psoriasis?
Ep 1162My Cancelled Lecture (5.11.2024)
In lieu of this weeks podcast, Dr. Jack Cush records his "Life Lessons (that keep changing) in Rheumatology Lecture. A lecture recently cancelled because some of this content was objectionable? (I dont think so!)
Ep 1161Roadblocks to reaching remission in lupus Sponsored by GSK US Medical Affairs
The 2023 EULAR recommendations for the management of lupus advocate for a treat-to-target approach, aiming for remission or low-level disease activity state.3 In this video, Dr. Michelle Petri summarizes the clinical criteria to attain these targets, and their association with reducing organ damage accrual.
Ep 1160Featured BSR Abstracts (5.3.2024)
Dr. Jack Cush muses on the news, journal reports, FDA announcements and the 2024 BSR abstracts just released.
